PROVIDING PATIENTS WITH THERAPEUTIC RELIEF FROM SERIOUS DISEASES WITH HIGH UNMET MEDICAL NEED

RELIEF THERAPEUTICS HOLDING AG

SIX: RLF.SW, OTCBB: RLFTF

SEPTEMBER 2021

SAFE HARBOR STATEMENT

Certain information set forth in this presentation contains "forward-looking information," including "future-oriented financial information" and "financial outlook," under applicable securities laws (collectively referred to herein as "forward-looking statements"). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the RELIEF THERAPEUTICS Holding AG ("Relief" or the "Company"); (ii) the expected development of the Company's business, projects and joint ventures; (iii) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (iv) sources and availability of third-party financing for the Company's projects; (v) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vi) discussion of the Company's material agreements; and (vii) future liquidity, working capital and capital requirements. Forward-looking statements are provided to allow potential investors and other parties the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment or other matters.

These statements are not a guarantee of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

COMPANY SNAPSHOT

COST-EFFECTIVE, CAPITAL-EFFICIENT APPROACH TO DRUG DEVELOPMENT AND COMMERCIALIZATION

Biopharmaceutical company with a deep clinical pipeline program focused on areas of high unmet need

- Targeting areas where clinical development can be swift and cost effective and distribution can be streamlined; initial focus on pulmonary and metabolic diseases
- Clinical programs based on molecules with well-established safety and tolerability profiles and either initial human activity or proof of concept, or a strong scientific rationale

Active strategy to expand pipeline

- Partnered with NRx Pharmaceuticals to develop and commercialize RLF-100™ (IV and inhaled formulations) for COVID-19-induced ARDS* and other indications in both acute and chronic lung diseases
- Collaborating with Acer Therapeutics for world-wide development and commercialization of ACER-001 for urea cycle disorders (UCDs) and maple syrup urine disease (MSUD)
- Acquisition of AdVita Lifescience adds synergistic programs in ARDS*, ALI*, CIP*, berylliosis and sarcoidosis
- Pursuing other in-licensing/M&A opportunities

Transformative APR acquisition creates forward integrated, highly nimble specialty drug company with core technology platforms for growth

- *Accretive to earnings on day one*; adds commercial infrastructure with potential to drive future product launches
- Diversifies development-stage pipeline, while adding synergistic programs and valuable out-licensing opportunities
- Marketed and late-stage products provide near- and mid-term revenue growth potential

*ARDS = Acute Respiratory Distress Syndrome; *ALI = Acute Lung Injury; *CIP = Checkpoint Inhibitor-Induced Pneumonitis

KEY INVESTMENT HIGHLIGHTS

Commercial-stage biopharmaceutical company focused on respiratory medicine and rare and specialty indications

- Flagship Golike marketed product line for management of patients with phenylketonuria (PKU)
- Established sales and marketing presence in major European countries (Germany, Italy)
- Virtual organizational model with lean operating structure and capital-efficient R&D engine
- Three Orphan Drug Designations: RLF-100 for sarcoidosis, APR-OD031 for PKU and APR-TD011 for epidermolysis bullosa (EB)

Two phase 3 programs with near-term milestones

- RLF-100 (aviptadil) for respiratory complications of COVID-19-induced ARDS* and NALI**
  - Synthetic human vasoactive intestinal peptide (VIP) with multifaceted MOA
  - EUA submission filed; Potential NDA submission by YE21 - both via partner, NRx (based on U.S. phase 2b/3 trial data of IV RLF-100 in COVID-19-induced ARDS*)
- ACER-001 to treat UCDs
  - Taste-masked, immediate-release formulation of sodium phenylbutyrate (NaPB)
  - Collaboration and license agreement with Acer Therapeutics for worldwide development and commercialization for UCDs and MSUD

Strong financial position to support multiple clinical programs through key value inflection points

- Available cash position of ~CHF30M (U.S.~$33M) as of end-July 2021 - operational runway into 2023
- Near-term objective to up-list to Nasdaq in the U.S.
- Potentially cash flow positive based on sales of aviptadil before YE-2021 if U.S. EUA is granted

*ARDS = Acute Respiratory Distress Syndrome; **NALI = Non-Acute Lung Injury

DIVERSIFIED LATE-STAGE PRODUCT CANDIDATE PIPELINE



APR PRODUCT PORTFOLIO & DEVELOPMENT PIPELINE





RLF-100

MAJOR NEAR-TERM MILESTONES IN COVID-19 AND POTENTIAL IN VARIOUS PULMONARY INDICATIONS

COVID-19: FACTS & FIGURES

THE WORST PUBLIC HEALTH DISASTER SINCE THE SPANISH FLU IN 1918

Coronavirus cases (globally)	**>208.9 Million**
Deaths (globally)	**~4.4 Million**

COVID-19: an extremely contagious viral infectious disease

Asymptomatic transmission	**20%–40%**
Basic reproduction number (R_0)	**2–8**

Case fatality worldwide	**~2%**
People over 60	**4% - 9%**
People over 80	**14% - 17%**
People over 80 + comorbidities	**>20%**

Current standard of care treatment for severe COVID-19 patients

Patients hospitalized in ICU	Personalized lung-protective mechanical ventilation or High Flow Nasal Oxygen	Remdesivir, antiviral (Gilead Sciences Inc.)	Steroids such as dexa-methasone

Total active cases vs. Total deaths

in Millions



Source: Worldometer.info

Laboratory-Confirmed COVID-19-Associated Hospitalizations 2020-2021

Preliminary cumulative rates per 100,00 population as of August 7, 2021

COVID-NET / Entire Network / 2020-2021 Cumulative Rate



RELIEF THERAPEUTICS

RLF-100: SYNTHETIC HUMAN VIP WITH MULTIMODAL MECHANISM OF ACTION

Vasoactive Intestinal Peptide (VIP or RLF-100)

- Produced throughout the body
- Concentrated in the lungs
- 70% of VIP bound to AT2
- Human peptide consisting of 28 amino acids
- Exogenously applied RLF-100 accumulates in the lung with extended half-life (half-life ~19 minutes)
- 20-year history of safety in humans

Binding to G protein-coupled receptors VPAC1, VPAC2 and PACAP-R1 triggers intracellular signaling

- Highest VPAC1 receptor density found in AT2 cells
- Significant modulation of the immune cell response (macrophages, CD4-T cells and tolerogenic dendritic cells) mediated by activation of the VPAC1 and VPAC2 receptors

Anti-inflammatory and immunomodulatory roles → immune cells

- Decreases pro-inflammatory cytokines (TNF-α, IL-6, INF-γ, ...)
- Increases expression of IL-10 and TGF-β

Vasodilatory and inotropic effects → vascular system

- Decreases vascular resistance
- Significantly increases arterial blood flow
- Primary positive ionotropic effect on cardiac muscle

Maintenance of bronchial system → lung

- Upregulates the production of surfactant
- Prevents cell death
- VIP-KO mice display airway hyper-responsiveness to noxious stimulus
- Reduces replication of SARS-CoV-2 virus in AT2 and monocytes

RELIEF THERAPEUTICS

RLF-100: POTENTIALLY TRANSFORMATIVE THERAPY FOR RESPIRATORY COMPLICATIONS OF COVID-19 INFECTION

SEVERAL TRIALS ONGOING

U.S. Emergency Use IND / Expanded Access Protocol (EAP) authorization

IV formulation

Ongoing; data from first 21 patients published online; close to 300 patients treated under EAP as of March 2021

U.S. phase 2b/3 study in patients with COVID-19 induced ARDS

IV formulation

Top-line 28-day and 60-day data announced in March 2021

Data shows evidence that RLF-100 helps prevent cytokine storm

U.S. phase 2b/3 study in patients with COVID-19 non-acute lung injury (NALI)

Inhaled formulation

Moderate to severe COVID-19 patients: study initiated in February 2021

U.S. NATIONAL TRIALS

I-SPY COVID-19 Clinical Trial sponsored by Quantum Leap

Inhaled formulation

RLF-100 one of the first drugs targeting Respiratory Failure in critically ill COVID-19 patients: currently underway

TESICO (Therapeutics for Severely Ill Inpatients with COVID-19) sponsored by the NIH

IV formulation

RLF-100 is one of two drugs included in the phase 3 multicenter trial to be conducted in the U.S. and multiple foreign countries

EUROPEAN CLINICAL TRIAL PROGRAM

Investigator-sponsored trial underway in Switzerland in prevention of COVID-19-related ARDS

Further **European clinical assessment** of RLF-100 under consideration and in preparation

COVID-19: SUSTAINED NEED FOR EFFECTIVE TREATMENTS EVEN IN A POST-VACCINE ENVIRONMENT

Vaccines protect people from infections by actively or passively strengthening the immune system

COVID-19 vaccines might not provide durable immunity due to:

- Spread of disease easily and widely through airborne droplets; undetectable spreading through symptom-free (asymptomatic) people
- Social distancing challenges and resistance to vaccination
- Consistent mutation of SARS-CoV-2 might undermine the immune system
- Data indicate people may lose immunity against coronavirus over time: observed antibody decreases
- Development of viral resistance against vaccines (novel variant strains, e.g., the highly contagious Delta variant, are known to possess vaccine-elicited immunity-evading mutations)
- Breakthrough viral infections of vaccinated people are becoming more common

Example – **influenza H1N1 virus**:

- Responsible for influenza pandemic in 2009 with ~100,000 – 400,000 deaths worldwide
- >10 years later: Virus still around, causing seasonal influenza infections
- H1N1 virus remains part of the annual influenza vaccination program

PARTNERING TO ENSURE RAPID CLINICAL DEVELOPMENT AND COMMERCIALIZATION OF RLF-100

GEOGRAPHIC RESPONSIBILITIES



PROFIT SPLIT PER COUNTRY

Country	Relief	NRx
U.S., Canada, Israel	50%	50%
Europe	85%	15%
Rest of World	80%	20%

PRODUCTION SCALE UP AND COMMERCIALIZATION:

Partner network

BACHEM — Specialized API manufacturer

nephron pharmaceuticals corporation — Fill/finish manufacturer

PolyPeptide GROUP — THE ULTIMATE PEPTIDE PARTNER

CDMO/peptides

Distribution partnerships (U.S. and ex-U.S.) under discussion

RLF-100 INTRAVENOUS 28- AND 60-DAY RESULTS

U.S. PHASE 2B/3 STUDY IN PATIENTS WITH COVID-19 INDUCED ARDS

Across all treated patients (196) and sites (10)

- **Primary endpoint met** – successful recovery from respiratory failure at days 28 (P=.014) and 60 (P=.013)
- **Meaningful survival benefit shown** (P=<.001) after controlling for ventilation status and treatment site

Clinically and statistically significant improvement in recovery from respiratory failure in patients at tertiary care hospitals treated by High Flow Nasal Cannulated Oxygen (HFNO) (N=127, P=.02), compared to those treated with mechanical or non-invasive ventilation*

PATIENTS AT TERTIARY CARE HOSPITALS WITH HFNC	Day-28	Day-60
Chance of successful recovery with RLF-100	71%	75%
Chance of successful recovery with placebo	48%	55%
	(P=.017)	(P=.036)
Survival to day 60 with RLF-100		84%
Survival to day 60 with placebo		60%
		(P=.007)

OVER TIME, HFNO HAS BECOME **THE** PREDOMINANT FORM OF TREATMENT IN COVID-19 RESPIRATORY FAILURE; MECHANICAL VENTILATION NOW TREATMENT OF LAST RESORT

* Prespecified analysis

Increased Recovery and Survival in Patients With COVID-19 Respiratory Failure Following Treatment with Aviptadil: Report #1 of the ZYESAMI COVID-19 Research Group (https://privpapers.ssrn.com/sol3/papers.cfm?abstract_id=3830051)

Data reported by partner, NRx, Pharmaceuticals., who is solely responsible for clinical development and regulatory submissions related to RLF-100 in the U.S.

RELIEF THERAPEUTICS

RLF-100 IN COVID-19: STEPS TO U.S. COMMERCIALIZATION

REGULATORY

IV in critical patients with ARDS

NRx submitted a U.S. FDA EUA application based on 60-day data

An NDA would be submitted thereafter, potentially by year-end 2021

SUPPLY CHAIN

Bachem
Long-time manufacturer of RLF-100
Ability to scale up rapidly
Cost effective manufacturing

Nephron
Core competencies in sterile injectables

PolyPeptide Group

Additional aviptadil acetate supplier

Additional potential manufacturing and distribution partnerships
(U.S. and ex-U.S.) under discussion

PRICING / COMMERCIALIZATION

Value-based pricing model considering efficacy profile and pharmacoeconomic benefits

Pricing will be subject to diagnosis-related group (DRG) pricing frameworks

Partnership with NRx to speed up commercialization in key markets

Relief to explore **PARTNERSHIPS** and **DISTRIBUTION AGREEMENTS** to facilitate access to RLF-100 as broadly as possible in regions wherein it does not intend to establish its own commercial infrastructure (e.g., emerging markets)


RELIEF
THERAPEUTICS
ACER-001
ADDRESSING RARE METABOLIC DISEASES

ACER-001: TASTE-MASKED, IMMEDIATE-RELEASE FORMULATION OF SODIUM PHENYLBUTYRATE (NAPB)

PROFILE

- Small molecule
- Microparticles consisting of core center, layer of active drug and taste-masking coating that quickly dissolves in the stomach but persists for up to five minutes in the mouth
- Avoids bitter taste while allowing for rapid systemic release

MOA

- UCDs: NaPB is a prodrug of phenylacetate, a NH4+ scavenger
- MSUD: NaPB is an allosteric inhibitor of BCKD kinase

LEAD INDICATIONS

- Urea Cycle Disorders (UCDs): Group of metabolic genetic diseases that lead to toxic build-up of NH4+ (ammonia)
- Maple Syrup Urine Disease (MSUD): Metabolic genetic disease that leads to toxic build-up of leucine and other branched-chain amino acids

OPPORTUNITY

- UCDs: >2,000 patients in the U.S.; ~700 patients treated with sodium/glycerol phenylbutyrate
  - Non-compliance is a major issue
- MSUD: ~800 eligible patients in the U.S.
  - No approved treatments
- Advantageous orphan pricing with robust program to support patient access and reimbursement

ACER-001 FOR ULTRA-RARE METABOLIC DISORDERS

A COST-EFFECTIVE, TASTE-MASKED ALTERNATIVE

- Taste-masked formulation **improves palatability & tolerability** vs BUPHENYL®
- Bioequivalence trials showed ACER-001 has **similar relative bio-availability** to BUPHENYL® under both fasted and fed conditions
- New fasted (pre-meal) dosing data suggest ability to **optimize Rx dosing approach***
- Pricing projected to be **significantly lower** than current RAVICTI ® price
- **Robust patient support services** program to remove barriers to care
- Payer engagement strategy to **alleviate insurance paperwork** and **support switching**
- Commitment to **support the UCD community** and on-going disease research



* Acer intends to seek FDA approval to market ACER-001 for administration initially under fed conditions for treatment of UCDs. Pre-meal administration of ACER-001 in UCDs will require additional nonclinical and clinical studies to demonstrate efficacy and safety and is subject to additional capital

** Payer Claims Data on File

ACER-001

COLLABORATION DEVELOPMENT & LICENSE AGREEMENT WITH ACER THERAPEUTICS

GEOGRAPHIC RESPONSIBILITIES



RELIEF THERAPEUTICS

Rest of World, including Europe

acertherapeutics

US | Canada | Brazil | Turkey | Japan

PROFIT SPLIT/ NET SALES ROYALTIES

Country	Relief	ACER
U.S., Canada, Brazil, Turkey, Japan (PROFIT)	60%	40%
Europe, Rest of World (NET SALES ROYALTY TO ACER)		15%

INITIAL CASH OUTLAY

- $1 million option payment to Acer in January 2021 for exclusive negotiation rights
- $4 million loan to Acer

WW COLLABORATION AND LICENSING AGREEMENT SIGNED IN MARCH 2021:

- Additional $10 million to Acer; plus, cancellation of $4 million loan
- Up to $20 million for U.S. development and launch costs (UCDs and MSUD) - $10 million paid to-date
- Acer - 15% net sales royalty on all revenues received in Relief's territories
- Potential total of $6 million in regulatory milestones to Acer*

505(B)(2) NDA: SUBMITTED TO FDA AUGUST 2021

- Potential regulatory decision H1 2022

MSUD: Clinical studies expected to begin in late 2021; pivotal program initiation in 2023 with results in 2024 and U.S. launch in 2025

*Based on first European (EU) marketing approvals for UCDs and MSUD

RELIEF THERAPEUTICS

APPLIED PHARMA RESEARCH S.A. (APR)

STRATEGIC FIT WITH DIFFERENTIATION AND GROWTH POTENTIAL

APR - A TRANSFORMATIVE ACQUISITION

Accelerates maturation into a fully integrated biopharmaceutical company

KEY SYNERGIES

- PHYSIOMIMIC™ and TEHCLO™ technology platforms provide a base for further portfolio expansion
- Opportunities to drive revenue growth and accelerate clinical development programs
- Commercial infrastructure is a springboard for future product launches
- Rich and diverse pipeline includes revenue-generating and key out-licensing opportunities.

A 2 Core Technologies

PHYSIOMIMIC technology | TEHCLO Applied NanoScience

B 2 Main Areas

Inherited Metabolic Diseases | Niche Disorders

C 2 Commercial Strategies

1. Direct Sales in EU and Distribution in RoW for Metabolic Products
2. Royalty-bearing Licensing for all Other Products

CONTRACT PRODUCT DEVELOPMENT

Incubator and an accelerator of third party's innovation

Providing state of the art support in the development of third party's ideas and products on a flexible contract basis

GOLIKE®: MAXIMIZING THE OPPORTUNITY IN PKU

INDICATION:

- Rare metabolic disorder that hinders the ability to create the enzyme to break down the amino acid phenylalanine, resulting in a dangerous build-up when eating foods containing protein or aspartame
- High levels can lead to neurophysiological dysfunction
- Patients require supplementation of amino acid-based foods for special medical purposes (FSMPs) to prevent protein deficiency and optimize metabolic control
- Compliance suffers as FSMPs have poor taste and odor, leading to diminished social interaction

MARKET OPPORTUNITY

- Approximately 350,000 people suffer from PKU*
- Current PKU FSMP market is approximately $400 million annually, worldwide
- Golike commercial rollout ongoing in Europe
- Expand on orphan drug designation of APR-OD031 for PKU

POTENTIAL BEST-IN-CLASS, DIFFERENTIATED PROFILE

- The first controlled-release, taste- and odor-masked amino acid mix that overcomes the issues of other FSMPs
- The first FSMP engineered with a drug delivery technology (Physiomimic Technology): offering improved metabolic management and better compliance for all PKU patients of all age groups

*National Organization for Rare Disorders (NORD)

APR-TD011: TARGETING EPIDERMOLYSIS BULLOSA (EB)

INDICATION

- Epidermolysis Bullosa (EB) is a group of rare, genetic, life threatening connective tissue disorders characterized by skin blistering throughout the body and risk of severe impact to internal organs
- Orphan Drug Designation granted in late 2019 by the U.S. FDA

MARKET OPPORTUNITY

- It is estimated that EB affects ~250,000 EB patients worldwide, with ~30,000 patients in the EU and ~20,000 patients in the U.S., according to the EB Research Partnership
- In a preliminary proof-of-concept clinical trial, EB patients administered APR-TD011 demonstrated improvement in skin blistering and tissue repairing in just two weeks of treatment – well tolerated and favorable safety profile established in over 300 subjects
- A potentially registration-quality phase 2/3 trial could start next year; U.S.$1bn/year market potential*

POTENTIAL BEST-IN-CLASS, DIFFERENTIATED PROFILE

- TD011 is a proprietary formulation of hypochlorous acid (HClO) sprayable solution that combines a strong antimicrobial action with anti-inflammatory properties and has the potential to become one of the first drugs approved for EB
- First product specifically developed for EB patients providing a complete treatment to prevent or reduce infections and inflammation through modulation of the wound microenvironment in order to accelerate a faster physiological wound healing

*Company reports

RELIEF THERAPEUTICS

CORPORATE INFORMATION

STRONG MANAGEMENT AND FIRM FINANCIAL BASE

STRONG INTERNATIONAL MANAGEMENT TEAM …

EXECUTIVE MANAGEMENT

Jack Weinstein
Chief Financial Officer

30+ years of financial sector and healthcare industry expertise

18 years healthcare investment banker on Wall Street

Former CFO of Catalyst Pharmaceuticals, a Nasdaq-listed biopharma firm

Dr. Taneli Jouhikainen
Chief Operating Officer

Over 25 years of life science experience

Joined from Savara where he was co-founder and President and COO

Served in senior executive roles at various life sciences firms, including Head of Clinical Development at Leiras (Schering AG)

Chris Stijnen
Chief Commercial Officer

Highly experienced executive in marketing, general management, access strategy and product development across many indications

Formerly at Bristol-Myers Squibb, responsible for marketing and commercialization of BMS portfolio in various international subsidiaries

Paolo Galfetti
President, Relief Europe

More than 20 years of life science experience, including managerial, R&D, business development, licensing and strategic planning

Nearly 17 years as CEO of APR Applied Pharma Research S.A.

Chartered financial accountant

Jeremy Meinen
VP Finance and Administration

Swiss certified public accountant

Expertise in financial consulting and controlling activities in various industries and former licensed audit expert

J. Paul Waymack, MD, ScD
Development & Regulatory Consultant

Formerly U.S. FDA medical officer, associate professor of surgery and director of the surgical intensive care unit at the NJ School of Medicine and Dentistry

Former chief of surgical studies at U.S. Army's Institute for Surgical Research

Jan-Jaap Scherpbier
Manufacturing & Supply Chain Consultant

Highly experienced pharmaceutical consultant

More than 25 years of expertise in the areas of regulatory affairs, life cycle management, pharmaceutical development and GMP requirements

… SUPPORTED BY A HIGHLY EXPERIENCED BOARD

BOARD OF DIRECTORS

Ram Selvaraju, Ph.D., MBA
Chairman of the Board

Managing Director & Senior Healthcare Analyst, H.C. Wainwright & Co., Equity Research Division

Former drug discovery pharmaceutical researcher at Serono in Switzerland

Tom Plitz, Ph.D.
Board Member

CEO of Chord Therapeutics SA, privately held biopharmaceutical firm

20+ years of R&D experience in senior management positions in the pharmaceutical industry

Patrice Jean, Ph.D.
Board Member

Chair of Hughes Hubbard's Life Sciences group

Over a decade of experience counseling leading and startup pharmaceutical, chemical and biotechnology companies in all areas of patent law

Paolo Galfetti
Board Member

Former CEO of APR Pharma and a Chartered Financial Accountant

Practical and managerial experience in clinical research, pharmaceutical discovery and development, business development and licensing as well as operational strategic management and restructuring

Member of several Pharma Licensing groups

CORPORATE INFORMATION:

SUFFICIENT RESOURCES TO SUPPORT CLINICAL DEVELOPMENT PROGRAMS ACROSS MULTIPLE INDICATIONS

RELIEF SHARES – LISTED ON SIX AND U.S. OTCQB

FIGURES*

SIX:	**RLF**
OTCQB:	**RLFTF**
Shares outstanding**:	**3,823,690,387**
Options outstanding:	**24,563,846**
Warrants outstanding:	**0**

CURRENT SHAREHOLDER STRUCTURE



FINANCING PLANS / OPTIONS

- Equity transactions
- Share Subscription Facility of up to CHF 50M (U.S.~$56M) in place
- Potential government stock piling of RLF-100
- Additional development and commercialization partnerships

- Available cash position as of July 31, 2021: ~CHF 30M (U.S.~$33M)
- Cash runway into 2023
- Low effective tax rate (Swiss Domicile): 14%

Plans to up-list near-term to the Nasdaq in the U.S.

*Figures as of July 31, 2021 ** Excluding treasury shares ≈ 586 million shares

NEWSFLOW AND UPCOMING INFLECTION POINTS

EXPANSION OF MANAGEMENT TEAM AS COMPANY EVOLVES | ADDITIONAL AGREEMENTS TO FURTHER DIVERSIFY PIPELINE



All timelines are subject to change pending regulatory and clinical development progress

BRINGING PATIENTS RELIEF FROM SERIOUS DISEASES WITH HIGH UNMET MEDICAL NEED

Looking to a Bright Future

- **Forward integrated** highly nimble specialty drug company
- **Potentially transformative** near-term regulatory decision for COVID-19 therapeutic, RLF-100
- **Multiple** therapeutic **shots on goal** for RLF-100
- **Deep pipeline** from phase 1 through phase 3
- Active strategy to **expand and diversify via in-licensing and M&A**
- APR acquisition brought commercial sales and infrastructure; **immediately accretive to earnings**
- **Major near-term milestones** anticipated for lead phase 3 programs: **RLF-100 and ACER-001**
- **Sufficient funds** to support clinical development programs across multiple indications

00

APPENDIX

RELIEF THERAPEUTICS: COMPANY HISTORY IN BRIEF



RELIEF THERAPEUTICS

RLF-100: ONGOING COVID-19 CLINICAL TRIALS

U.S. PHASE 2B/3 TRIAL IN PATIENTS WITH COVID-19 NALI (INHALED FORMULATION)

RLF-100 (Aviptadil Acetate) for the Treatment of Severe COVID-19

- 144 participants
- Randomized, placebo-controlled, multicenter, parallel assignment, quadruple masked trial
- Patients to be treated with inhaled RLF-100 by mesh nebulizer 100µg 3x daily
- Primary outcome: Progression to respiratory failure over 28 days
- Study initiated February 2021
- Enrollment completion slated to be achieved in October 2021
- Top-line results expected by year-end 2021 or early 2022

I-SPY PHASE 2 COVID-19 TRIAL, SPONSORED BY QUANTUM LEAP (INHALED FORMULATION)*

Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients

- Up to 1,500 participants
- Randomized, parallel assignment trial, Bayesian design, from 5 up to 8 arms
- Aviptadil + Remdesivir arm: Remdesivir (IV) as SOC + Aviptadil 100µg (microgram) in 1ml normal saline per dose, via nebulizer, administered q8H, for a maximum of 14 days
- Primary endpoint: Time to recover to a durable level 4 (or less) on the WHO COVID-19 ordinal scale for clinical improvement [up to 28 days]

PHASE 3 TESICO TRIAL, SPONSORED BY THE NIH (IV FORMULATION)*

Therapeutics for Severely Ill Inpatients with COVID-19

- Up to 640 participants
- International, adaptive, randomized, parallel assignment, triple masked, placebo-controlled multicenter trial
- Evaluating the safety and efficacy of investigational agents (RLF-100, Remdesivir) aimed at improving outcomes for patients with acute respiratory failure related to COVID-19
- Aviptadil + Remdesivir + SOC arm (corticosteroid): Remdesivir + Aviptadil administered by IV infusion over 12 hours per day for 3 days
- Primary endpoint: Recovery at 90 days

- **Relief is not required to fund the I-SPY or TESICO trial execution costs; these studies are supported by the Quantum Leap Healthcare Collaborative and the National Institutes of Health (NIH), respectively**
- **The company is solely responsible for providing study drug in the context of these trials**

RELIEF THERAPEUTICS